The short interest in BioScrip (NASDAQ:BIOS) has declined from 14,579,843 on May 31,2016 to 14,392,842 on June 15,2016. The change was measured at 187,001 shares or 1.3%. The leftover shorts were 21.8% of the floated shares. The days to cover are 20, given the average daily volume of 709,007 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
BioScrip (NASDAQ:BIOS): The stock opened at $2.54 on Friday but the bulls could not build on the opening and the stock topped out at $2.63 for the day. The stock traded down to $2.48 during the day, due to lack of any buying support eventually closed down at $2.49 with a loss of -9.78% for the day. The stock had closed at $2.76 on the previous day. The total traded volume was 1,953,506 shares.
The company shares have dropped -33.60% from its 1 Year high price. On Jun 29, 2015, the shares registered one year high at $3.93 and the one year low was seen on Jan 14, 2016. The 50-Day Moving Average price is $2.62 and the 200 Day Moving Average price is recorded at $2.15.
Stocks of BioScrip (NASDAQ:BIOS) rallied by 0.81% during the past week but lost 8.79% on a 4-week basis. The company has outperformed the S&P 500 by 2.48% in the past week but underperformed the index by 6.03% in the last 4 weeks.
BioScrip, Inc. is engaged in providing infusion and home care management solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payers and pharmaceutical manufacturers to provide patients access to post-acute care services. Its segments include Infusion Services and Pharmacy Benefit Management (PBM) Services. Its Infusion Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Its PBM Services segment consists of integrated PBM services, which primarily consists of discount card programs that provide alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. It provides products, services and condition-specific clinical management programs for health conditions, such as gastrointestinal abnormalities, infectious diseases, and others.